Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis…
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company…
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma…
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough…
Ghana follows Rwanda in approving BioUcenta™, Africa’s first approved ranibizumab biosimilarACCRA, Ghana and KIGALI, Rwanda, Jan. 13, 2026 (GLOBE NEWSWIRE)…
– Collaboration is designed to improve analytical speed and accuracy of Freenome's blood-based cancer screening tests – BRISBANE, Calif., Jan. 12, 2026…
The breakthrough tackles a longstanding challenge in genetic medicine with the goal of developing a new generation of curative cell…
With the Function Connector, Members Can Access Their Personalized Health Data and a Summary of Biomarker Results, Directly Within Claude…
Reshaping the Global Drug Development Landscape with the Industry's Only Natively AI-Powered Omnimodal Foundation Model for Tumor and Immune BiologySAN…
IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision…